Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8% - Should You Sell?

Key Points

• Maze Therapeutics shares fell 6.8% to $26.71, with trading volume 42% below the stock’s average. The company has a $1.49 billion market capitalization and its shares remain below both the 50-day and 200-day moving averages.
• Analyst sentiment remains broadly positive, with an average rating of “Buy” and a consensus price target of $66, despite Truist lowering its target from $68 to $64 and Weiss Ratings maintaining a sell rating.
• The company reported a quarterly EPS loss of $0.45, slightly worse than the expected $0.43 loss. Insiders sold 141,470 shares worth about $3.9 million over the past 90 days, though the transactions were made under pre-arranged Rule 10b5-1 plans.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price fell 6.8% during trading on Monday . The stock traded as low as $26.42 and last traded at $26.71. 388,599 shares traded hands during mid-day trading, a decline of 42% from the average daily volume of 669,093 shares. The stock had previously closed at $28.65.

Analyst Ratings Changes

Several analysts have weighed in on MAZE shares. Truist Financial dropped their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a "buy" rating on the stock in a research report on Tuesday, April 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics has an average rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Trading Down 6.4%

The stock has a 50-day moving average of $27.54 and a 200 day moving average of $33.56. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.49 billion, a PE ratio of -10.60 and a beta of 2.22.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.02). The business had revenue of $20.00 million for the quarter. As a group, sell-side analysts anticipate that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the sale, the insider directly owned 26,250 shares of the company's stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the sale, the chief marketing officer directly owned 15,000 shares in the company, valued at $393,300. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 141,470 shares of company stock valued at $3,902,714 over the last 90 days. Insiders own 5.30% of the company's stock.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of MAZE. Royal Bank of Canada boosted its position in Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares during the period. California State Teachers Retirement System increased its holdings in shares of Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock valued at $55,000 after purchasing an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company's stock valued at $247,000 after purchasing an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in Maze Therapeutics during the fourth quarter worth $39,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source